Security
Drugs Made In America Acquisition II Corp. Right · DMIIR
DMIIRNASDAQRightCurrentCIK 2040475Updated Oct 6, 2026
DMIIR price & chart
Loading TradingView…
NASDAQ:DMIIR on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
10-Q filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
10-K filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| AssetsUSD | 501,005,711Source | — | 514,100,156Source | — | 509,725,411Source | — | 504,959,837Source | 138,064Source |
| Current assets: | ||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | 174,974Source | — | 347,720Source | — | 223Source | — |
| Assets, CurrentUSD | 896,356Source | — | 217,823Source | — | 351,761Source | — | 26,037Source | 59,615Source |
| LIABILITIES AND EQUITY | ||||||||
| LiabilitiesUSD | 18,177,345Source | — | 18,144,574Source | — | 18,166,285Source | — | 17,800,864Source | 254,783Source |
| Stockholders’ equity: | ||||||||
| Common Stock, Value, IssuedUSD | 1,557Source | — | 1,369Source | — | 1,369Source | — | 1,369Source | 1,437Source |
| Additional Paid in CapitalUSD | — | — | — | — | — | — | — | 33,563Source |
| Retained Earnings (Accumulated Deficit)USD | -17,282,546Source | — | -17,928,120Source | — | -17,815,893Source | — | -17,776,196Source | -151,719Source |
| Stockholders' Equity Attributable to ParentUSD | -17,280,989Source | -6,684Source | -17,926,751Source | -214,119Source | -17,814,524Source | -176,046Source | -17,774,827Source | -116,719Source |
| Liabilities and EquityUSD | 501,005,711Source | — | 514,100,156Source | — | 509,725,411Source | — | 504,959,837Source | 138,064Source |
| Current liabilities: | ||||||||
| Liabilities, CurrentUSD | 677,345Source | — | 644,574Source | — | 666,285Source | — | 300,864Source | 254,783Source |
| Accounts Payable, CurrentUSD | 4,592Source | — | 12,253Source | — | 49,166Source | — | 99,359Source | — |
| Additional Financial Items | ||||||||
| Accrued Liabilities, CurrentUSD | 5,843Source | — | 69,159Source | — | 53,957Source | — | 88,343Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||
| Changes in operating assets and liabilities: | |||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | -22,246Source | 11,283Source | 99,359Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | -102,503Source | -10,044Source | -1,018,231Source | — |
| Cash flows from investing activities: | |||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | -500,000,000Source | — |
| Cash flows from financing activities: | |||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | 450,000Source | — | 501,001,419Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | 315,087Source | 120,070Source | 174,974Source | 4,394Source | 347,720Source | 6,991Source | 223Source | 17,035Source |
| Additional Financial Items | |||||||||
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | 553,748Source | — |
| General and Administrative ExpenseUSD | — | 155,513Source | — | 112,227Source | 38,073Source | 132,030Source | 59,327Source | 488,385Source | — |
| Investment Income, InterestUSD | — | 109,355Source | — | 4,508,683Source | — | 4,439,850Source | — | 4,933,800Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | -46,158Source | — | 4,396,456Source | -38,073Source | 4,337,820Source | -59,327Source | 4,187,050Source | — |
| Nonoperating Income (Expense)USD | — | 109,355Source | — | 4,508,683Source | — | 4,469,850Source | — | 4,675,435Source | — |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | — | 77,799Source | — |
| Operating ExpensesUSD | — | — | — | 112,227Source | 38,073Source | 132,030Source | 59,327Source | 488,385Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | -155,513Source | -112,227Source | -38,073Source | -132,030Source | -59,327Source | -488,385Source |
| Net Income (Loss) Attributable to ParentUSD | — | -46,158Source | 4,396,456Source | -38,073Source | 4,337,820Source | -59,327Source | 4,187,050Source |
| Additional Financial Items | |||||||
| General and Administrative ExpenseUSD | — | 155,513Source | 112,227Source | 38,073Source | 132,030Source | 59,327Source | 488,385Source |
| Investment Income, InterestUSD | — | 109,355Source | 4,508,683Source | — | 4,439,850Source | — | 4,933,800Source |
| Nonoperating Income (Expense)USD | — | 109,355Source | 4,508,683Source | — | 4,469,850Source | — | 4,675,435Source |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | 77,799Source |
| Operating ExpensesUSD | — | — | 112,227Source | 38,073Source | 132,030Source | 59,327Source | 488,385Source |
| Other Expenses | — | — | —Source | — | — | — | — |
Filing attachments
ea028546801ex4-5.htm · 10-K · 2026-04-15
Exhibit 4.5 DRUGS MADE IN AMERICA ACQUISITION II CORP. DESCRIPTION OF SECURITIES The following summary of the material terms of the securities of Drugs Made In America Acquisition II Corp. (“we,” “us,” “our” or “the Company”) is not intended to be a complete summary of the rights and preferences of such securities and is subject to and qualified by reference to our amended and restated memorandum and articles of association incorporated by reference as an exhibit to the Company’s Annual Repor…
Read attachment ↗